Future of Health in Digital Therapeutics
Digital therapeutics are a novel category of medical interventions that have the potential to disrupt the future of healthcare models.
What are Digital Therapeutics?
Digital therapeutics (DTx) are software-based products for the prevention, management and treatment of health conditions. They are defined by the Digital Therapeutic Alliance as evidence-based therapeutic interventions that are driven by high-quality software programs to prevent, manage or treat a medical disorder or disease. Digital therapeutics are a subcategory of digital medicine products, which in turn are a subset of digital health. A feature of DTx is that they require both clinical evidence and evidence from real-world outcomes. As such, they need to be reviewed and approved by regulatory bodies for claims of safety, risk and efficacy.
Will life sciences companies see DTx as an opportunity or a threat?
Traditional life science companies may see digital therapeutics either as a potential threat to their business model or as an opportunity to innovate. On the one hand, digital therapeutics could compete with existing pharmacological treatments for market share. On the other hand, a digital therapeutic offering could play the role of differentiator, as an attractive value proposition for those pharmaceutical companies that have historically been interested in ’beyond the pill’ value delivery.
Traditional pharma and medtech companies have a first-mover advantage to capitalise on the opportunity presented by digital therapeutics, before players in other industries, like technology giants, take over. Benefits for life sciences companies from becoming active in the development of novel digital therapeutics are:
Strategic choices for life sciences companies
Life sciences companies have a unique opportunity to structure their strategic approach to enter or consolidate their position in the digital therapeutics space. There are some fundamental questions that biopharma and medtech companies will need to answer. We have formulated these questions around a strategic choice cascade framework.
Why banks struggle to create inspiring content
The future of health will look very different from today
Swiss banks: How to master client experience in the digital age
Gabriele is a Partner in Monitor Deloitte’s Life Sciences Strategy practice with focus on Commercial Transformation. Gabriele brings 20 years of management consulting experience in Life Sciences across mature and emerging countries, including more than 10 years at BCG and 4 years at EY where he was leading the Life science commercial practice. He has served most of the top global pharmaceutical companies and a range of mid-size, specialty and biotech clients.
Carlo is a Partner in our Life Sciences practice and leads the Customer Strategy team in Switzerland. He has over 15 years of experience in management consulting. Carlo led multiple projects at both headquarter and affiliate level, from commercial (digital) strategy definition to organisational design and implementation of large project transformations. He has primarily supported clients in the pharma, biotech and MedTech sector, but he vast experience in advising retail & consumer goods corporations. Carlo holds an MBA Columbia Business School in New York and graduated in Business Administration at Bocconi University in Milan.
Vito is a senior strategy consultant in the Customer Strategy & Applied Design team based in Zurich. He brings over 5 years of experience in the life sciences and consumer health sector. His focus lies at the intersection of commercial strategy and innovation, ranging from developing market access-, go-to-market- and digital- strategies to designing target operating models for large-scale commercial transformation programmes.